Among gastrointestinal cancers, a recent phase III trial with an anti–PD-1 mAb for patients with advanced gastric cancers (GC) or esophageal cancers (EC) showed a survival benefit, resulting in the approval of anti–PD-1 mAb for treating GC or EC in Japan (6, 7). Here, PDCD1 is linked to esophageal cancer.